Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CD278 Rat anti-Mouse, Brilliant Violet 421, Clone: 7E.17G9, BD

Rat Monoclonal Antibody

Manufacturer:  BD Biosciences 564070

Catalog No. BDB564070


Add to cart

Description

Description

The 7E.17G9 antibody reacts with CD278, the Inducible Costimulatory molecule (ICOS), a 47-57 kDa homodimeric glycoprotein of the CD28 family of costimulatory molecules. ICOS is expressed on subpopulations of CD4-CD8- and CD4+CD8- (but not CD4-CD8+ or CD4+CD8+) thymocytes, on some T-cell lines, and on small numbers of peripheral leukocytes. It is upregulated on T lymphocytes following activation via the T-cell receptor. The T-cell activation marker H4 is the same molecule asICOS. ICOS is a costimulatory receptor, and its ligand on antigen-presenting cells has been called B7RP-1, GL50, B7h, B7-H2, or LICOS. There is considerable evidence that the interaction of ICOS with its ligand is involved in the regulation of many, but not all, T-cell-mediated immune responses.

Specifications

Specifications

CD278
7E.17G9
Brilliant Violet 421
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
Rat
IgG2b, κ
RUO
Primary
Murine
Flow Cytometry
0.2mg/mL
ICOS; Ailim; CCLP; CRP-1; Ly115; Inducible T-cell costimulator
Affinity Purified
Mouse Icos cDNA and ICOS hexahistidine fusion protein
50μg
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Monoclonal
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit